FDA Inspection 1306730 — Cagatay Arslan, M.D.
The FDA completed an inspection of Cagatay Arslan, M.D. on February 19, 2026 in Imbatli. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 19, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Imbatli (Turkey)
Additional Details
Clinical Investigator (CI)